PharmaShots | Incisive News in 3 Shots

Subscribe Now

Advanced Prostate Cancer

Myovant's Orgovyx (relugolix) Receives the US FDA's Approval as the First Oral GnRH Receptor Antagonist for Advanced Prostate Cancer

Myovant's Orgovyx (relugolix) Receives the US FDA's Approval as the First Oral GnRH Receptor Antagonist for Advanced Prostate Canc...

December 15, 2020

Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer

Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer

November 20, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us